P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P3, N=152, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=444 --> 152

We leveraged the Phase III Fondazione Italiana Linfomi FOLL12 trial, which treated patients with advanced-stage FL with R-CHOP or R-Bendamustine, to evaluate the role of myeloid CH at baseline and after chemoimmunotherapy (CIT). Patients acquiring fit DDR clones (N = 37) had inferior long-term outcomes, including independent increased risk of second malignancies (hazard ratio [HR] 2.63, P = 0.035) that developed in 28 patients, and shorter OS (HR 3.28, P = 0.008). CH emerges as a novel and potentially valuable biomarker in FL, capable of predicting long-term toxicities that are key endpoints in indolent lymphoid malignancies characterized by long-lasting survival.

He received intensive multimodal immunotherapy, including high-dose methylprednisolone, intravenous immunoglobulin, plasma exchange, and rituximab. This is the first report of a seizure-free, triple-positive autoimmune encephalitis subtype presenting with prominent cognitive impairment, thereby expanding the clinical spectrum of recently described overlapping autoimmune encephalitis syndromes. The low titer and rapid seroreversion of mGluR5 antibodies suggest a possible bystander phenomenon secondary to blood-brain barrier disruption.

However, interpretation of these findings is limited by the non-randomized design and differences in rituximab exposure between groups, which may have contributed to the observed outcomes and limited definitive conclusions. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Later, the patient received systemic chemotherapy with R-CHOP for eight cycles...This case presents unique features such as chronic abdominal pain and anorexia, which can lead to misdiagnosis due to a broad differential. There is a need to provide knowledge of primary colon lymphoma to ensure early diagnosis and favorable outcomes.

P1, N=90, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jul 2028 --> Sep 2029 | Trial primary completion date: Jul 2028 --> Sep 2029

P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute

In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.

P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2026 --> Jan 2026

P1, N=12, Recruiting, University of Utah | Not yet recruiting --> Recruiting

P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Dec 2026 --> Jun 2027